Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NRAS Wildtype”

34 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 34 results

Not applicableStudy completedNCT02322736
What this trial is testing

Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR

Who this might be right for
Metastatic Colorectal Cancer
Amgen 218
Large-scale testing (Phase 3)Looking for participantsNCT06662786
What this trial is testing

Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Who this might be right for
Colorectal Neoplasms
Janssen Research & Development, LLC 1,000
Testing effectiveness (Phase 2)WithdrawnNCT01960023
What this trial is testing

Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
NSABP Foundation Inc
Not applicableStudy completedNCT03914170
What this trial is testing

Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
Institut du Cancer de Montpellier - Val d'Aurelle 70
Testing effectiveness (Phase 2)Study completedNCT03446157
What this trial is testing

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

Who this might be right for
Cancer of the ColonColon CancerColon Neoplasms+2 more
UNC Lineberger Comprehensive Cancer Center 24
Post-approval studies (Phase 4)UnknownNCT02301962
What this trial is testing

Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer

Who this might be right for
Cancer
Dr. Reddy's Laboratories Limited 58
Testing effectiveness (Phase 2)Ended earlyNCT02587650
What this trial is testing

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

Who this might be right for
ALK Fusion Protein ExpressionBRAF wt AlleleInvasive Skin Melanoma+12 more
University of California, San Francisco 1
Not applicableActive Not RecruitingNCT02394834
What this trial is testing

An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer

Who this might be right for
Colorectal Cancer
Takeda 757
Testing effectiveness (Phase 2)Study completedNCT02063529
What this trial is testing

FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Sun Yat-sen University 101
Testing effectiveness (Phase 2)Looking for participantsNCT07257653
What this trial is testing

The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer

Who this might be right for
Colorectal NeoplasmsRASBRAF+2 more
Zhejiang University 70
Large-scale testing (Phase 3)Looking for participantsNCT07252232
What this trial is testing

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Who this might be right for
Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc. 500
Early research (Phase 1)Study completedNCT02065063
What this trial is testing

Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

Who this might be right for
Cancer
GlaxoSmithKline 28
Early research (Phase 1)Ended earlyNCT02199223
What this trial is testing

Regorafenib + Panitumumab for Colorectal Cancers

Who this might be right for
KRAS and NRAS Wild-type Colorectal Cancer
University of Utah 2
Testing effectiveness (Phase 2)Ended earlyNCT03580382
What this trial is testing

Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma

Who this might be right for
Melanoma
NYU Langone Health 3
Testing effectiveness (Phase 2)Study completedNCT03442569
What this trial is testing

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Who this might be right for
Colon Cancer
UNC Lineberger Comprehensive Cancer Center 56
Testing effectiveness (Phase 2)UnknownNCT04466254
What this trial is testing

Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 75
Testing effectiveness (Phase 2)Ended earlyNCT01508000
What this trial is testing

Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases

Who this might be right for
Colorectal Cancer MetastaticLiver MetastasesKRAS Wild Type Colorectal Cancer
European Organisation for Research and Treatment of Cancer - EORTC 44
Testing effectiveness (Phase 2)UnknownNCT03457896
What this trial is testing

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

Who this might be right for
Metastatic Colorectal Cancer
NSABP Foundation Inc 35
Testing effectiveness (Phase 2)UnknownNCT02296203
What this trial is testing

Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).

Who this might be right for
Metastatic Colorectal Cancer
Gruppo Oncologico del Nord-Ovest 27
Large-scale testing (Phase 3)Ended earlyNCT05223673
What this trial is testing

Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Institut de Recherches Internationales Servier 7
Next Page